Stock PLSE PULSE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Delayed Nasdaq
Other stock markets
 03:46:47 2024-06-04 pm EDT 		5-day change 1st Jan Change
14.15 USD +4.12% Intraday chart for Pulse Biosciences, Inc. +6.31% +15.69%
May. 20 Pulse Biosciences Moves New Record Date for Rights Offering MT
May. 14 Pulse Biosciences Appoints Burke Barrett as President, CEO MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pulse Biosciences, Inc Announces CEO Changes
Pulse Biosciences, Inc Announces Executive Changes
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sector Update: Health Care Stocks Slide Late Afternoon
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Sector Update: Health Care Stocks Ease Late Afternoon
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise
Sector Update: Health Care Stocks Rise Tuesday Afternoon
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PLSE Stock
  4. News Pulse Biosciences, Inc.
  5. Other languages